List view / Grid view

Kinases

 

webinar

Designing a Novel Cancer Drug: From Hit ID to Candidate

28 March 2017 | By Charles River

Discover how their multidisciplinary approach to hit ID, design and synthesis of novel chemical templates and development of targeted in vitro and in vivo assays resulted in the nomination of the first development candidate in just over two years...

article

PIM/FLT3 dual inhibition

13 May 2016 | By Wojciech Czardybon, PhD, Project Manager, Discovery Laboratory Manager, Selvita S.A.

In this article, Wojciech Czardybon of Selvita discusses the potential of PIM/FLT3 dual inhibition in treating acute myeloid leukaemia and other cancers...